NanoRepro

NanoRepro CROIC

The Cash Return on Invested Capital (CROIC) of NanoRepro (NN6.DE) as of Oct 27, 2026 is 24.80 %. In the previous year, Cash Return on Invested Capital (CROIC) was -25.42 % — a change of -197.55% (higher).

CROIC

24.80 %

YoY

-197.55%

Last updated:

Cash Return on Invested Capital (CROIC) of NanoRepro is 2024 24.80 % . Cash Return on Invested Capital (CROIC) of NanoRepro was 2023 -25.42 % . It decreases by -197.55% higher compared to the previous year.

The NanoRepro CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2017
-29.01 EUR
Jan 1, 2018
-12.44 EUR
Jan 1, 2019
-26.59 EUR
Jan 1, 2020
-12.02 EUR
Jan 1, 2021
14.13 EUR
Jan 1, 2022
20.74 EUR
Jan 1, 2023
-25.42 EUR
Jan 1, 2024
24.80 EUR
The NanoRepro CROIC history
YEARCROICYoY
24.80 %-197.55%
-25.42 %-222.55%
20.74 %+46.81%
14.13 %-217.50%
-12.02 %-54.78%
-26.59 %+113.74%
-12.44 %-57.11%
-29.01 %+20.12%
-24.15 %-40.99%
-40.92 %+8.77%
-37.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NanoRepro Stock analysis

What does NanoRepro do? The Nanorepro AG was founded in 1998 in Marburg an der Lahn and has since developed into a leading company in the development and production of diagnostic rapid tests and self-tests. The company has been listed on the Frankfurt Stock Exchange since 2006 and has its headquarters in the university city of Marburg. Nanorepro's business model focuses on the production and distribution of innovative, reliable, and easy-to-use self-tests for the medical field. The company concentrates on the practical application of the tests - they should be simple, fast, and user-friendly. Nanorepro's core competence lies in the design, production, and distribution of rapid tests and self-tests for the medical field. The company relies on close cooperation with other companies and research institutions to continuously improve the tests and develop new products. Nanorepro focuses on various areas, including the manufacturing of rapid tests and self-tests for the diagnosis of infectious diseases. In addition, the company also offers tests to check pregnancy status or determine ovulation. Nanorepro's range of products also includes self-tests for the early detection of diseases such as diabetes. With its wide range of products, the company is able to address a large customer base and achieve a positive market position. One key product of Nanorepro is the early pregnancy test. This product is easy to handle and allows women to quickly and safely determine if they are pregnant or not. Nanorepro also offers an ovulation test to help women determine the timing of ovulation. Another test offered by the company is the Lyme borreliosis self-test, which allows for the detection of antibodies to Lyme borreliosis. Nanorepro also offers numerous tests for diagnosing infectious diseases. These include tests that can diagnose bacterial or viral infections such as streptococcal infections or hepatitis B and C. The tests are highly accurate and reliable, enabling quick diagnosis and treatment. Another area in which Nanorepro is expanding is the development of self-tests for the early detection of cancer. For this purpose, the company works closely with scientific and research institutions to continuously improve the tests and make them even more precise and reliable. Nanorepro places a strong emphasis on quality control and safety in the production of the tests. The products are CE-certified, ensuring high quality and safety for the user. In addition, the company has been certified according to the standards of the International Quality Management System ISO 13485, guaranteeing a high standard in the production and marketing of medical devices. Overall, Nanorepro AG has established itself as a leading company in the field of rapid tests and self-tests. With its wide range of products and constant willingness to innovate, the company is able to quickly and effectively respond to the requirements of customers and partners. The company's extensive experience in the field of medical diagnostics contributes to Nanorepro being perceived as a reliable partner in medical technology. NanoRepro is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NanoRepro stock

Cash Return on Invested Capital (CROIC) of NanoRepro is 24.80 % in 2024.

Cash Return on Invested Capital (CROIC) of NanoRepro changed from -25.42 % to 24.80 %, representing a -197.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) NanoRepro since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s NanoRepro with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — NanoRepro

All Key Metrics — NanoRepro